Randomized study of the effects of empagliflozin and topiramate dual therapy on anthropometric and metabolic indices in non-diabetic individuals with overweight/obesity on a calorie-restricted diet

• Published in: Eating and weight disorders 2024-10, Vol.29 (1), p.64-14, Article 64
• Main Authors: Abiri, Behnaz, Ramezani Ahmadi, Amirhossein, Hosseinpanah, Farhad, Valizadeh, Ali, Zarghi, Afshin, Valizadeh, Majid
• Format: Article
• Language: English
• Subjects: Adult; Anti-Obesity Agents - therapeutic use; Benzhydryl Compounds - therapeutic use; Blood Glucose - drug effects; Blood Glucose - metabolism; Blood Pressure - drug effects; Body Composition - drug effects; Body Mass Index; Caloric Restriction; Calories; Diabetes; Dietary restrictions; Double-Blind Method; Drug Therapy, Combination; Empagliflozin; Female; Glucosides - therapeutic use; Humans; Italian Society of Obesity (SIO) Reviews; Male; Medicine; Medicine & Public Health; Middle Aged; Non-diabetic individuals; Obesity; Obesity - complications; Obesity - diet therapy; Obesity - drug therapy; Overweight; Overweight - diet therapy; Overweight - drug therapy; Psychiatry; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Topiramate; Topiramate - therapeutic use; Treatment Outcome; Waist Circumference - drug effects; Weight Loss - drug effects; Weight loss products
• ISSN: 1590-1262; 1124-4909; 1590-1262
• DOI: 10.1007/s40519-024-01692-2

Objectives The objective of this study was to evaluate the effectiveness of the combined use of empagliflozin (EMPA) and topiramate (TPM) versus a placebo in overweight/obese individuals without diabetes on a calorie-restricted diet. Methods In this study, 44 non-diabetic and overweight/obese subjects who were on a calorie restricted diet were randomly assigned into 2 groups: (1) Participants received a 10 mg EMPA tablet daily plus TPM tablet (at the 1st week 25 mg once a day and from the second week 25 mg twice a day); (2) Participants received an empagliflozin placebo (daily) plus a topiramate placebo (as mentioned for topiramate tablet in group 1), for 12 weeks. At baseline and weeks 4, 8, 12, weight, height, body mass index (BMI), waist circumference (WC), and body composition were evaluated. Before and after the intervention, blood pressure, C reactive protein, and glucose and lipid profile parameters were measured. Results The EMPA/TPM group, compared to placebo, had a greater percent change of weight at week 12 (− 8.92 ± 1.80 vs. − 4.93 ± 1.17). The intervention group had a greater percent change of fat mass and fat percent at week 12 (P